Talis Biomedical Corporation Operating Cash Flow
Talis Biomedical Corporation reported Operating Cash Flow of -$17.76 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2024-08-19
- Talis Biomedical Corporation net cash provided by (used in) operating activities for the quarter ending 2024-06-30 was -$11.33M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for the quarter ending 2024-03-31 was -$6.43M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for the quarter ending 2023-12-31 was -$11.36M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for the quarter ending 2023-09-30 was -$11.14M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for fiscal 2023 was -$53.24M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for fiscal 2022 was -$100.14M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for fiscal 2021 was -$171.38M.
- Talis Biomedical Corporation net cash provided by (used in) operating activities for fiscal 2020 was -$87.02M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$11.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$17.76M 10-Q · filed 2024-08-19 | -$29.11M derived: sum of 3 quarters · filed 2024-08-19 | -$40.26M derived: sum of 4 quarters · filed 2024-08-19 |
| 2024-03-31 | -$6.43M 10-Q · filed 2024-05-08 | -$17.78M derived: sum of 2 quarters · filed 2024-05-08 | -$28.93M derived: sum of 3 quarters · filed 2024-05-08 | -$43.20M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-12-31 | -$11.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$22.50M derived: sum of 2 quarters · filed 2024-03-28 | -$36.77M derived: sum of 3 quarters · filed 2024-08-19 | -$53.24M 10-K · filed 2024-03-28 |
| 2023-09-30 | -$11.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$25.42M derived: sum of 2 quarters · filed 2024-08-19 | -$41.88M 10-Q · filed 2023-11-14 | -$55.43M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-06-30 | -$14.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$30.74M 10-Q · filed 2024-08-19 | -$44.28M derived: sum of 3 quarters · filed 2024-08-19 | -$65.10M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | -$16.46M 10-Q · filed 2024-05-08 | -$30.01M derived: sum of 2 quarters · filed 2024-05-08 | -$50.83M derived: sum of 3 quarters · filed 2024-05-08 | -$72.84M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$34.37M derived: sum of 2 quarters · filed 2024-03-28 | -$56.38M derived: sum of 3 quarters · filed 2024-03-28 | -$100.14M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$20.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$42.84M derived: sum of 2 quarters · filed 2023-11-14 | -$86.59M 10-Q · filed 2023-11-14 | -$127.33M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$22.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$65.77M 10-Q · filed 2023-08-10 | -$106.51M derived: sum of 3 quarters · filed 2023-08-10 | -$181.26M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$43.76M 10-Q · filed 2023-05-11 | -$84.50M derived: sum of 2 quarters · filed 2023-05-11 | -$159.25M derived: sum of 3 quarters · filed 2023-05-11 | -$192.66M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$40.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$115.49M derived: sum of 2 quarters · filed 2023-03-22 | -$148.90M derived: sum of 3 quarters · filed 2023-03-22 | -$171.38M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$74.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$108.16M derived: sum of 2 quarters · filed 2022-11-03 | -$130.64M 10-Q · filed 2022-11-03 | -$167.33M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$33.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$55.90M 10-Q · filed 2022-08-02 | -$92.59M derived: sum of 3 quarters · filed 2022-08-02 | -$125.38M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$22.48M 10-Q · filed 2022-05-10 | -$59.18M derived: sum of 2 quarters · filed 2022-05-10 | -$91.97M derived: sum of 3 quarters · filed 2022-05-10 | -$103.93M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$36.69M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$69.49M derived: sum of 2 quarters · filed 2022-03-15 | -$81.44M derived: sum of 3 quarters · filed 2022-03-15 | -$87.02M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$32.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-16 | -$44.75M derived: sum of 2 quarters · filed 2021-11-16 | -$50.33M 10-Q · filed 2021-11-16 | |
| 2020-06-30 | -$11.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$17.54M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$5.58M 10-Q · filed 2021-05-13 |